Evidence map›Paper›PMID 31817884›Full record

ReviewInternational journal of molecular sciences2019

Alternative Strategies to Inhibit Tumor Vascularization.

Alessia Brossa, Lola Buono, Sofia Fallo, Alessandra Fiorio Pla, Luca Munaron, Benedetta Bussolati

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Antifibrotic therapy to normalize the tumor microenvironment.Journal of translational medicine · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alessia BrossaDepartment of Molecular Biotechnology and Health Sciences; Universitty of Torino, 10126 Torino, Italy.
Lola BuonoDepartment of Molecular Biotechnology and Health Sciences; Universitty of Torino, 10126 Torino, Italy.
Sofia FalloDepartment of Molecular Biotechnology and Health Sciences; Universitty of Torino, 10126 Torino, Italy.
Alessandra Fiorio PlaDepartment of Life Science and Systems Biology; University of Torino, 10126 Torino, Italy.ORCID 0000-0003-4576-1594
Luca MunaronDepartment of Life Science and Systems Biology; University of Torino, 10126 Torino, Italy.ORCID 0000-0001-9247-4446
Benedetta BussolatiDepartment of Molecular Biotechnology and Health Sciences; Universitty of Torino, 10126 Torino, Italy.ORCID 0000-0002-3663-5134
University of Turin · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG2015 16973
6 · The paper itself

Abstract

Endothelial cells present in tumors show different origin, phenotype, and genotype with respect to the normal counterpart. Various mechanisms of intra-tumor vasculogenesis sustain the complexity of tumor vasculature, which can be further modified by signals deriving from the tumor microenvironment. As a result, resistance to anti-VEGF therapy and activation of compensatory pathways remain a challenge in the treatment of cancer patients, revealing the need to explore alternative strategies to the classical anti-angiogenic drugs. In this review, we will describe some alternative strategies to inhibit tumor vascularization, including targeting of antigens and signaling pathways overexpressed by tumor endothelial cells, the development of endothelial vaccinations, and the use of extracellular vesicles. In addition, anti-angiogenic drugs with normalizing effects on tumor vessels will be discussed. Finally, we will present the concept of endothelial demesenchymalization as an alternative approach to restore normal endothelial cell phenotype.

Indexed as

Angiogenesis InhibitorsAnimalsHumansNeoplasmsNeovascularization, PathologicTumor MicroenvironmentAngiogenesis Inhibitorsanti-angiogenic drugsendothelial cellsendothelial demesenchymalizationendothelial vaccinationnormalizationtumor vasculogenesis

Identifiers

PMID31817884
PMCPMC6940973
OpenAlexW2992396726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.